"One of the first-to-file opportunities that Mr. Sobti referred to was valacyclovir hydrochloride, a generic version of GlaxoSmithKline PLC's anti-herpes medicine Valtrex, which Ranbaxy launched with 180-day marketing exclusivity in the U.S. in November last year."